Truist Lifts Price Targets on IQVIA and Zymeworks, Keeps Buy Ratings
Truist Securities raised its IQVIA target to $346 from $329 and Zymeworks to $35 from $34, keeping Buy ratings on both, Dow Jones Newswires reports.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Truist Securities raised its price target on IQVIA Holdings to $346 per share from $329 and kept its Buy rating on the stock, according to a report by Dow Jones Newswires that cites Benzinga ratings data.
The same brokerage lifted its target on Zymeworks to $35 per share from $34 and maintained its Buy recommendation. Both updates were recorded at 17:10 and 17:29 GMT on October 28, 2026.
why it matters
Price target revisions from a single brokerage are routine market events and usually have only a short-term effect on share prices. For investors, they signal how analysts view IQVIA and Zymeworks rather than evidence of changes in their financial results, which the source does not describe.
tags
instruments
sources
- IQVIA Holdings Price Target Raised to $346.00/Share From $329.00 by Truist Securities — Dow Jones Newswires, 28 October 2026 at 17:10 UTC
- Zymeworks Price Target Raised to $35.00/Share From $34.00 by Truist Securities — Dow Jones Newswires, 28 October 2026 at 17:29 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗